

FORM PT01449
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.


2500.097US2

SERIAL NO.

09/065,330

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



APPLICANT

Ameae M. Walker

FILED

April 23, 1998

GROUP

2744-1646

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
CA	A1	4 7 2 5 5 4 0	2/16/88	Underberg et al.			
CA	A2	4 7 2 5 5 4 9	2/16/88	Cooke et al.			
CA	A3	5 0 7 5 2 2 4	12/24/91	Seeburg et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANS.? (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

CA	C1	Arámburo et al., "Phosphorylation of Prolactin and Growth Hormone," <i>Journal of Molecular Endocrinology</i> , 8, pp. 183-191 (1992).
	C2	Brooks et al., "Preparative Purification of Phosphorylated and Nonphosphorylated Bovine Prolactins," <i>Molecular and Cellular Endocrinology</i> , 99, pp. 301-305 (1994).
	C3	Clevenger et al., "Expression of Prolactin and Prolactin Receptor in Human Breast Carcinoma," <i>American Journal of Pathology</i> , 146(3), pp. 695-705 (1995).
	C4	Cunningham et al., "Mediation of the Binding of Human Growth Hormone to the Human Prolactin Receptor," <i>Science</i> , 250, pp. 1709-1712 (1990).
	C5	Fuh et al., "Mechanism-based Design of Prolactin Receptor Antagonists," <i>The Journal of Biological Chemistry</i> , 268, pp. 5376-5381 (1993).
	C6	Goffin et al., "Alanine-Scanning Mutagenesis of Human Prolactin: Importance of the 58-74 Region for Bioactivity," <i>Molecular Endocrinology</i> , 6(9), pp. 1381-1392 (1992).
CA	C7	Ho et al., "Secretion of Phosphorylated and Non-Phosphorylated Monomer Prolactin Isoforms During Rat Pregnancy and Pseudopregnancy," <i>Endocrine Journal</i> , 1, pp. 435-439 (1993).

EXAMINER

C. Saoud

DATE CONSIDERED

6/15/00

* EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

FORM PT01449
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.


2500.097US2

SERIAL NO.

09/065,330

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



APPLICANT

Ameae M. Walker

FILED

April 23, 1998

GROUP

~~2744~~ 1646

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANS.? (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

CA	C8	Kim and Brooks, "Isolation and Characterization of Phosphorylated Bovine Prolactin," <i>Biochem. J.</i> , 295, pp. 41-47 (1993).
	C9	Luck et al., "Analysis of Disulphide Bridge Function in Recombinant Bovine Prolactin Using Site-Specific Mutagenesis and Renaturation Under Mild Alkaline Conditions: A Crucial Role for the Central Disulphide Bridge in the Mitogenic Activity of the Hormone," <i>Protein Engineering</i> , 5(6), pp. 559-567 (1992).
	C10	Luck et al., "Bioactive Recombinant Methionyl Bovine Prolactin: Structure-Function Studies Using Site-Specific Mutagenesis," <i>Molecular Endocrinology</i> , 3(5), pp. 822-831 (1989).
	C11	Luck et al., "Single Amino Acid Substitutions in Recombinant Bovine Prolactin that Markedly Reduce its Mitogenic Activity in Nb2 Cell Cultures," <i>Molecular Endocrinology</i> , 5(12), pp. 1880-1886 (1991).
	C12	Paris et al., "Bacterial Production and Purification of Recombinant Human Prolactin," <i>Biotechnology and Applied Biochemistry</i> , 12, pp. 436-449 (1990).
	C13	Rhee et al., "Biological Activity and Immunological Reactivity of Human Prolactin Mutants," <i>Endocrinology</i> , 136(11), pp. 4990-4995 (1995).
u	C14	Walker, Ameae M., "Phosphorylated and Nonphosphorylated Prolactin Isoforms," <i>Trends Endocrinol. Metab.</i> , 5, pp. 195-200 (1994).

EXAMINER

C Saoud

DATE CONSIDERED

6/15/00

* EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

FORM PT01449
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

2500.097US2

SERIAL NO.

09/065,330

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

JUL 23 1998

APPLICANT

Ameae M. Walker

FILED

April 23, 1998

GROUP

~~2744~~ 1646

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANS.? (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

C15	Chen et al., "Development of a Recombinant Prolactin (PRL) Receptor Antagonist," Abstract presented at the International Pituitary Congress 4th Satellite Meeting of the International Congress of Endocrinology, San Diego, California, June 16-18, 1996.
C16	Wang and Walker, "Dephosphorylation of Standard Prolactin Produces a More Biologically Active Molecule: Evidence for Antagonism between Nonphosphorylated and Phosphorylated Prolactin in the Stimulation of Nb ₂ Cell Proliferation," <i>Endocrinology</i> , 133(5), pp. 2156-2160 (1993).
C17	Dialog Search to Prolactin-, Antagonist- and Hyperprolactinemia, January 1996.
C18	Maciejewski et al., "Mutation of Serine 90 to Glutamic Acid Mimics Phosphorylation of Bovine Prolactin," <i>The Journal of Biological Chemistry</i> , 270(46), pp. 27661-37665 (1995).
C19	Goffin et al., "Evidence for a Second Receptor Binding Site on Human Prolactin," <i>The Journal of Biological Chemistry</i> , 269(51), pp. 32598-32606 (1994).
C20	Chen et al., "Development of Recombinant Human Prolactin Receptor Antagonists by molecular Mimicry of the Phosphorylated Hormone," <i>Endocrinology</i> , 139(2), pp. 609-616 (1998).
C21	Wang et al., "Identification of the Major Site of Rat Prolactin Phosphorylation as Serin 177," <i>The Journal of Biological Chemistry</i> , 271(5), pp. 2462-2469 (1996).

EXAMINER

C Saoud

DATE CONSIDERED

6/15/00

* EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

FORM PT01449
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.


2500.097US2

SERIAL NO.

09/065,330

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



APPLICANT

Ameae M. Walker

FILED

April 23, 1998

GROUP

2744 1646

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANS.? (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

C22	Or	Oetting et al., "Phosphorylation of Prolactin," <i>The Journal of Biological Chemistry</i> , 261, v. 4, pp. 1649-1652 (1986).
C23		Greenan et al., "Biosynthesis of the Secreted 24K Isoforms of Prolactin," <i>Endocrinology</i> , 125, v. 4, pp. 2041-2048 (1989).
C24		Krown et al., "Prolactin Isoform 2 is an Autocrine Growth Factor for GH ₃ Cells," <i>Endocrinology</i> , 131, v. 2, pp. 595-602 (1992).
C25		Ho et al., "Secretion of Specific Nonphosphorylated and Phosphorylated Rat Prolactin Isoforms at Different Stages of the Estrous Cycle," <i>Neuroendocrinology</i> , 58, pp. 160-165 (1993).
C26	CA	Lorenson et al., "Intragranular Prolactin Phosphorylation and Kallikrein Cleavage are Regulated by Zinc and Other Divalent Cations," <i>Endocrine</i> , 4, v. 3, pp. 249-257 (1996).

EXAMINER

C. Saoud

DATE CONSIDERED

6/15/00

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to